

In The United States Patent and Trademark Office

In re application of:
Koenig, Scott *et al.*

Appl. No. **10/643,857**

Filed: **August 14, 2003**

For: **FcγRIIB-Specific Antibodies
and Methods of Use Thereof**

Art Unit: **1644**

Examiner: **Dahle, Chun Wu**

Atty. Docket: **1301.0019C**

Confirmation No.: **1191**

Supplemental Reply Pursuant to 37 C.F.R. §1.116

Filed via EFS-Web
Mail Stop After Final
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In further response to the Final Office Action dated November 30, 2007, Applicants
Do not enter submit this supplemental response. Kindly consider the submission.

C.D.

03/17/2008

Amendments to the Specification: none

Amendments to the Claims: none.

Amendments to the Drawings: none

Applicants' Remarks: begin on page 2 of this submission.

No fee, other than those provided for on any accompanying Fee Transmittal Form are believed to be due in order for the timely consideration of this supplemental Reply. In the event that the Commissioner determines that an additional fee is required in for consideration of this submission, the U.S. Patent and Trademark Office is hereby authorized to charge any SMALL ENTITY fee deficiency, or credit any overpayment, to Deposit Account No. **05-0460** referencing Attorney Docket No. **1301.0019C**.